Cardiology

Top Story

New monthly dose of alirocumab granted approval

April 25, 2017

The FDA has approved a 300-mg once-monthly dose of alirocumab for injection, Regeneron and Sanofi announced.

The approval of the new dose is based on results from phase 3 ODYSSEY CHOICE I study of alirocumab (Praluent, Sanofi/Regeneron), according to a press release from the companies.

In the Journals

Benefit of ezetimibe/simvastatin for acute coronary syndrome questionable

April 25, 2017
New findings suggest that the trial population of IMPROVE-IT were younger, healthier and received more optimal secondary prevention therapies than current qualifying…
In the Journals

ACC/AHA/HRS guideline provides recommendations for diagnosis, prognosis for syncope

April 25, 2017
The American College of Cardiology, the American Heart Association and Heart Rhythm Society published guidelines for the assessment and treatment of patients with
In the Journals

Physical activity associated with reduced odds of subclinical myocardial damage

April 24, 2017
Physical activity is associated with decreased risk for myocardial damage in high-risk patient groups and may mitigate the association between obesity and myocardial…
In the JournalsPerspective

HEART score to assess patients with chest pain underutilized in EDs

April 24, 2017
Using the History, ECG, Age, Risk factors and initial Troponin, or HEART, score during initial assessment of patients with chest pain is safe; however, physicians did…
More News Headlines »
Advertisement
Advertisement